FDA orders Cadila to clean up its act at sterile plant in India 

FDA headquarters
The FDA has issued a warning letter to Cadila's Moraiya, Ahmedabad, plant, its second in four years. (FDA)

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different tablet products that were cross-contaminated with API residue from another drug during production. 

Cadila’s response to the agency was that what the FDA called “significant cross-contamination” didn’t pose a risk to patients, which the agency completely dismissed as scientifically unsound.  

RELATED: Cadila recalls tens of thousands of bottles of antidepressant

The findings were laid out in a recent warning letter that piled problems on top of the plant at Moraiya, Ahmedabad, after a Form 483 had already savaged it for having grimy aseptic equipment and unacceptable work methods that could lead to microbial contamination of sterile injected products.  

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Cadila acknowledged this month that it had received the warning letter but downplayed the potential impact. It said the action would not hurt its U.S. business and that it expects to continue to produce drugs at the Moraiya facility, its largest serving the U.S. market.  

The warning letter ordered Cadila to completely remake its cleaning procedures and explain to the FDA the “worst case” cleaning situations it faced and how it intends to overcome them. 

RELATED: Cadila's U.S. facility in St. Louis cited by FDA for 11 observations: report

Cadila has for years faced FDA concerns over its manufacturing at different plants. This is the second warning letter in four years for Cadila’s Moraiya plant. It and a sterile injectables facility in Vadodara, India, were called out for manufacturing issues in a warning letter in late 2015. 

The FDA also has found issues with Zydus Cadila’s Nesher Pharmaceuticals plant in St. Louis. An inspection there last summer resulted in 11 observations.

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.